Pacira BioSciences (PCRX) CCO receives 51,714-share restricted stock grant

Rhea-AI Filing Summary

Pacira BioSciences, Inc. reported an equity award to Chief Commercial Officer Brendan Teehan. On February 11, 2026, he acquired 51,714 shares of common stock at a price of $0 under a grant classified as an award or other acquisition.

The award represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, as long as he remains in continuous service with the company on each vesting date. After this grant, Teehan directly beneficially owns 100,934.268 shares of Pacira common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Teehan Brendan

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		A		51,714(1)	A	$0	100,934.268	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Pacira BioSciences (PCRX) report for Brendan Teehan?

Pacira BioSciences reported that Chief Commercial Officer Brendan Teehan received an equity award of 51,714 shares of common stock on February 11, 2026, at a price of $0 per share, classified as a grant, award, or other acquisition under a Form 4 filing.

How many Pacira (PCRX) shares does Brendan Teehan own after this Form 4 transaction?

Following the reported award, Brendan Teehan beneficially owns 100,934.268 shares of Pacira common stock directly. This total reflects the addition of 51,714 awarded shares, which are represented by restricted stock units that convert into common shares upon vesting over time.

What type of equity was granted to Pacira’s Chief Commercial Officer in this Form 4?

The filing shows an award of restricted stock units for 51,714 shares. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock, subject to a vesting schedule and the executive’s continued service with the company through future vesting dates.

What is the vesting schedule for Brendan Teehan’s restricted stock units at Pacira (PCRX)?

The restricted stock units vest in four equal annual installments starting on February 15, 2027. Vesting requires that Brendan Teehan remain in continuous service with Pacira as of each vesting date, linking the equity compensation to ongoing employment and long-term company commitment.

Was cash paid for the Pacira (PCRX) shares reported in this Form 4?

No cash was paid for these shares; the transaction price per share is reported as $0. The Form 4 classifies the activity as a grant, award, or other acquisition, reflecting equity-based compensation rather than an open-market stock purchase for cash.

Is Brendan Teehan’s ownership in Pacira shares direct or indirect after this award?

The filing shows Brendan Teehan’s ownership as direct, indicated by the code “D” in the ownership form column. After the award of restricted stock units, he directly beneficially owns 100,934.268 shares of Pacira BioSciences common stock according to the reported Form 4 data.